General Atlantic, L.P.
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 12, 2024), General Atlantic, L.P. reported 18 stock positions worth $3.5 billion. Its top holding was Alignment Healthcare (ALHC) at 20.5% of the portfolio, followed by XP Class A (XP, 15.1%) and Dlocal (DLO, 14.5%). Compared with Q2 2024, it sold out of 1 and reduced 1. The biggest sale was Alkami Technology (ALKT, shares −10%).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0001017645
- Portfolio Value
- $3.5B (Q3 2024)
- SEC Filing
- 0000950142-24-002746 ↗ filed Nov 12, 2024
Holdings Value
Holdings 18 stocks · $3.5B
| ALHC Alignment Healthcare Inc. | 20.50% | 60,993,323 | $720.9M | No change |
| XP XP Inc. Class A | 15.11% | 29,617,733 | $531.3M | No change |
| DLO Dlocal Ltd. | 14.53% | 63,906,695 | $511.3M | No change |
| SQSP Squarespace Inc. Class A | 14.01% | 10,611,073 | $492.7M | No change |
| ALKT Alkami Technology Inc. | 13.92% | 15,520,318 | $489.5M | Reduce -9.7% |
| CNTA Centessa Pharmaceuticals Ltd. | 4.40% | 9,681,818 | $154.8M | No change |
| AKRO Akero Therapeutics Inc. | 4.27% | 5,233,989 | $150.2M | No change |
| PHVS Pharvaris NV | 3.97% | 7,531,252 | $139.5M | No change |
| EWCZ European Wax Center Inc. Class A | 2.53% | 13,110,492 | $89.2M | No change |
| BLND Blend Labs Inc. Class A | 2.04% | 19,132,440 | $71.7M | No change |
| RPRX Royalty Pharma PLC Class A | 1.21% | 1,500,000 | $42.4M | No change |
| THRD Third Harmonic Bio Inc. | 1.14% | 2,958,762 | $40.1M | No change |
| IMCR Immunocore Holdings PLC-ADR | 1.12% | 1,261,684 | $39.3M | No change |
| RSKD Riskified Ltd. Class A | 0.72% | 5,324,998 | $25.2M | No change |
| SLRN Acelyrin Inc. | 0.41% | 2,889,668 | $14.2M | No change |
| CONTEXTLOGIC INC - A | 0.09% | 609,616 | $3.3M | No change |
| GROV Grove Collaborative Holdings | 0.04% | 936,020 | $1.3M | No change |
| ADAG Adagene Inc.-ADR | 0.02% | 264,000 | $586K | No change |
Portfolio Sells Q2 2024 → Q3 2024
Portfolio Buys Q2 2024 → Q3 2024
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 12 | $2.9B | LFTO, DLO, CHYM, ALKT, XP |
| Q1 2026 | 12 | $2.1B | DLO, CHYM, XP, ALKT, PHVS |
| Q4 2025 | 13 | $2.9B | DLO, CHYM, XP, ALKT, ALHC |
| Q3 2025 | 16 | $3.3B | DLO, XP, ALHC, CHYM, ALKT |
| Q2 2025 | 15 | $3.6B | DLO, CHYM, ALHC, XP, AKRO |
| Q1 2025 | 15 | $3.0B | ALHC, DLO, XP, ALKT, AKRO |
| Q4 2024 | 16 | $2.8B | DLO, ALHC, ALKT, XP, CNTA |
| Q3 2024 | 18 | $3.5B | ALHC, XP, DLO, SQSP, ALKT |
| Q2 2024 | 19 | $3.2B | XP, DLO, ALKT, ALHC, SQSP |
| Q1 2024 | 22 | $4.3B | DLO, XP, ALKT, HRT, SQSP |